RAPP
Rapport TherapeuticsRAPP
RAPP
About: Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Employees: 69
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
289% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 9
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
10% more funds holding
Funds holding: 70 [Q4 2024] → 77 (+7) [Q1 2025]
4.4% more ownership
Funds ownership: 99.99% [Q4 2024] → 104.39% (+4.4%) [Q1 2025]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 4 (-1) [Q1 2025]
41% less capital invested
Capital invested by funds: $649M [Q4 2024] → $382M (-$267M) [Q1 2025]
50% less call options, than puts
Call options by funds: $10K | Put options by funds: $20K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$28
150%
upside
Avg. target
$28
150%
upside
High target
$28
150%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Jason Butler | 150%upside $28 | Market Outperform Initiated | 8 Apr 2025 |
Financial journalist opinion
Based on 4 articles about RAPP published over the past 30 days
Positive
MarketBeat
2 days ago
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical companies experience when a key positive trial result is announced or an important drug receives government approval.
Neutral
GlobeNewsWire
1 week ago
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025 Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025
Neutral
GlobeNewsWire
2 weeks ago
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
BOSTON and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences.
Neutral
GlobeNewsWire
3 weeks ago
Rapport Therapeutics to Host 2025 Investor and Analyst Day
BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced it will host its inaugural Investor and Analyst Day on Monday, June 2, 2025, in New York City. The event will also be webcast live.
Neutral
GlobeNewsWire
1 month ago
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025 RAP-219 Phase 2a trial in patients with bipolar mania remains on track to commence in the third quarter of 2025, with topline results expected in the first half of 2027 Company to host inaugural Investor and Analyst Day on June 2, 2025, featuring presentations from management team and key opinion leader Dr. Jacqueline French Ended the quarter with $285.4 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2026 BOSTON and SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the first quarter ending March 31, 2025, and provided a business update. “2025 represents a transformational year for Rapport as we prepare to deliver our initial proof-of-concept data for RAP-219 from the Phase 2a trial in patients with refractory focal epilepsy and progress our pipeline-in-a-product strategy with the initiation of our bipolar mania trial.
Neutral
GlobeNewsWire
1 month ago
Mise à disposition du rapport financier annuel 2024
Communiqué de presse Mise à disposition du rapport financier annuel 2024 Dijon, France le 30 avril 2025 (17h45 CET) -- CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique spécialisée en phase avancée de développement et d'enregistrement de ZEPIZURE®, sa solution d'urgence pour la gestion des crises d'épilepsie, annonce avoir mis à la disposition du public et déposé auprès de l'Autorité des Marchés Financiers son rapport financier annuel 2024. Le rapport financier annuel 2024 peut être consulté sur le site internet de la société.
Neutral
GlobeNewsWire
1 month ago
Rapport Therapeutics to Participate in Upcoming Investor Conferences
BOSTON and SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in three upcoming investor conferences. Jones Trading Virtual CNS Symposium - fireside chat on Tuesday, April 29, 2025, from 11:00-11:25am ET.
Neutral
NYTimes
1 month ago
Meloni and Trump: An Oval Office Meeting With Rapport and Banter
In their meeting, President Trump made clear that he had special regard for Prime Minister Giorgia Meloni of Italy. She said he had accepted an invitation to go to Rome.
Neutral
GlobeNewsWire
2 months ago
Crédit Agricole Ille-et-Vilaine : Communiqué de mise à disposition du rapport financier 2024
Caisse régionale de Crédit Agricole Mutuel d'Ille-et-Vilaine, société coopérative à capital variable, agréée en tant qu'établissement de crédit, société de courtage d'assurance immatriculée auprès de l'ORIAS sous le n°07 023 057.Siège social : 4, rue Louis Braille - 35136 Saint-Jacques de la Lande.N° SIREN : 775.590.847 Communiqué de mise à disposition du rapport financier annuel 2024 de la Caisse régionale du Crédit Agricole d'Ille-et-Vilaine Le Crédit Agricole d'Ille-et-Vilaine informe le public que son rapport financier annuel a été déposé auprès de l'AMF et est disponible sur le site internet de la Société. Il peut être consulté sur le site Internet du Crédit Agricole d'Ille-et-Vilaine : www.ca-illeetvilaine.fr, dans l'espace « Informations règlementaires et financières » / Rapports annuels et semestriels.
Neutral
GlobeNewsWire
2 months ago
Bpce: Mise à disposition du document d'enregistrement universel 2024 et du rapport financier annuel du Groupe BPCE
Paris, le 21 mars 2025 Mise à disposition du document d'enregistrement universel 2024 et du rapport financier annuel du Groupe BPCE Le Groupe BPCE informe que le document d'enregistrement universel 2024 a été déposé auprès de l'Autorité des Marchés Financiers (AMF) le 21 mars 2025 sous le n° D.25-0132. Ce document est tenu gratuitement à la disposition du public dans les conditions prévues par la réglementation en vigueur.
Charts implemented using Lightweight Charts™